WordNet

move from one place to another; "transfer the data"; "transmit the news"; "transfer the patient to another hospital"
the act of transfering something from one form to another; "the transfer of the music from record to tape suppressed much of the background noise" (同)transference
transferring ownership (同)transference
application of a skill learned in one situation to a different but similar situation (同)transfer of training, carry-over
someone who transfers or is transferred from one position to another; "the best student was a transfer from LSU" (同)transferee
a ticket that allows a passenger to change conveyances
change from one vehicle or transportation line to another; "She changed in Chicago on her way to the East coast" (同)change
transfer somebody to a different position or location of work (同)reassign
move around; "transfer the packet from his trouser pockets to a pocket in his jacket" (同)shift
transfer from one place or period to another; "The ancient Greek story was transplanted into Modern America" (同)transpose, transplant
cause to change ownership; "I transferred my stock holdings to my children"
any of a large group of nitrogenous organic compounds that are essential constituents of living cells; consist of polymers of amino acids; essential in the diet of animals for growth and for repair of tissues; can be obtained from meat and eggs and milk and legumes; "a diet high in protein"
an animal sterol that is normally synthesized by the liver; the most abundant steroid in animal tissues (同)cholesterin
formed by reaction between an acid and an alcohol with elimination of water

PrepTutorEJDIC

(…から…へ)〈人・物〉‘を'『移す』,移転させる,乗り換えさせる《+名〈人・物〉+from+名+to+名》 / (…から…へ)〈権利・財産など〉‘を'譲り渡す,移転する《+名〈権利・財産〉+from+名+to+名》 / 〈絵画・デザインなど〉‘を'写す,転写する / 〈人が〉(ある人・場所から他の人・場所などへ)『移る』,移される;転任する,転任させられる《+from+名+to+名》 / (…から…へ)列車(バスなど)を乗り換える《+from+名+to+名》 / 〈U〉〈C〉(…を)『移すこと』,(…が)移転されること《+of+名》;転任,転校 / 〈C〉移る人(物),移される人(物);転校生,転任者 / 〈C〉乗り換え切符 / 〈C〉乗り換え場所 / 〈C〉写し絵
蛋白(たんばく)質
コレステロール(胆汁・血液・神経組織などの脂肪性成分)
エステル(酸とアルコールから水を分離してできる化合物の総称)

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/09/12 16:49:18」(JST)

wiki en

Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein, is a plasma protein that facilitates the transport of cholesteryl esters and triglycerides between the lipoproteins. It collects triglycerides from very-low-density (VLDL) or low-density lipoproteins (LDL) and exchanges them for cholesteryl esters from high-density lipoproteins (HDL), and vice versa. Most of the time, however, CETP does a heteroexchange, trading a triglyceride for a cholesteryl ester or a cholesteryl ester for a triglyceride.

Genetics

The CETP gene is located on the sixteenth chromosome (16q21).

Role in disease

Rare mutations leading to reduced function of CETP have been linked to accelerated atherosclerosis.^[3] In contrast, a polymorphism (I405V) of the CETP gene leading to lower serum levels has also been linked to exceptional longevity ^[4] and to metabolic response to nutritional intervention.^[5] However, this mutation also increases the prevalence of coronary heart disease in patients with hypertriglyceridemia.^[6] The D442G mutation, which lowers CETP levels and increases HDL levels also increases coronary heart disease.^[3]

Elaidic acid, a major component of trans fat, increases CETP activity.^[7]

Pharmacology

As HDL can alleviate atherosclerosis and other cardiovascular diseases, and certain disease states such as the metabolic syndrome feature low HDL, pharmacological inhibition of CETP is being studied as a method of improving HDL levels.^[8] To be specific, in a 2004 study, the small molecular agent torcetrapib was shown to increase HDL levels, alone and with a statin, and lower LDL when co-administered with a statin.^[9] Studies into cardiovascular endpoints, however, were largely disappointing. While they confirmed the change in lipid levels, most reported an increase in blood pressure, no change in atherosclerosis,^[10]^[11] and, in a trial of a combination of torcetrapib and atorvastatin, an increase in cardiovascular events and mortality.^[12]

A compound related to torcetrapib, Dalcetrapib (investigative name JTT-705/R1658), was also studied, but trials have ceased.^[13] It increases HDL levels by 30%, as compared to 60% by torcetrapib.^[14] Two CETP inhibitors are currently under development. One is Merck's MK-0859 anacetrapib, which in initial studies did not increase blood pressure.^[15] The other is Eli Lilly's evacetrapib, which failed in Phase 3 trials.

Interactive pathway map

Click on genes, proteins and metabolites below to link to respective articles. ^{[§ 1]}

[[File:

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

|px|alt=Statin Pathway edit]]

File:StatinPathway_WP430.png

Statin Pathway edit

^ The interactive pathway map can be edited at WikiPathways: "Statin_Pathway_WP430".

References

^ ^a ^b ^c GRCh38: Ensembl release 89: ENSG00000087237 - Ensembl, May 2017
^ "Human PubMed Reference:".
^ ^a ^b Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR (June 1996). "Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels". J Clin Invest. 97 (12): 2917–23. PMC 507389 . PMID 8675707. doi:10.1172/JCI118751.
^ Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, Lipton R, Cheng S, Shuldiner AR (October 2003). "Unique lipoprotein phenotype and genotype associated with exceptional longevity". JAMA. 290 (15): 2030–40. PMID 14559957. doi:10.1001/jama.290.15.2030.
^ Darabi M, Abolfathi AA, Noori M, Kazemi A, Ostadrahimi A, Rahimipour A, Darabi M, Ghatrehsamani K (2009). "Cholesteryl ester transfer protein I405V polymorphism influences apolipoprotein A-I response to a change in dietary fatty acid composition". Horm Metab Res. 41 (7): 554–8. PMID 19242900. doi:10.1055/s-0029-1192034.
^ Bruce C, Sharp DS, Tall AR (1 May 1998). "Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia". J Lipid Res. 39 (5): 1071–8. PMID 9610775.
^ Abbey M, Nestel PJ (March 1994). "Plasma cholesteryl ester transfer protein activity is increased when trans-elaidic acid is substituted for cis-oleic acid in the diet". Atherosclerosis. 106 (1): 99–107. PMID 8018112. doi:10.1016/0021-9150(94)90086-8.
^ Barter PJ, Brewer HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR (February 2003). "Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis". Arterioscler Thromb Vasc Biol. 23 (2): 160–7. PMID 12588754. doi:10.1161/01.ATV.0000054658.91146.64.
^ Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ (April 2004). "Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol". N Engl J Med. 350 (15): 1505–15. PMID 15071125. doi:10.1056/NEJMoa031766.
^ Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Lasala GP, Tuzcu EM (March 2007). "Effect of torcetrapib on the progression of coronary atherosclerosis". N Engl J Med. 356 (13): 1304–16. ISSN 0028-4793. PMID 17387129. doi:10.1056/NEJMoa070635.
^ Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML (April 2007). "Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia". N Engl J Med. 356 (16): 1620–30. PMID 17387131. doi:10.1056/NEJMoa071359.
^ "Pfizer Stops All Torcetrapib Clinical Trials in Interest of Patient Safety" (Press release). U.S. Food and Drug Administration. 2006-12-03.
^ El Harchaoui K, van der Steeg WA, Stroes ES, Kastelein JJ (August 2007). "The role of CETP inhibition in dyslipidemia". Curr Atheroscler Rep. 9 (2): 125–33. PMID 17877921. doi:10.1007/s11883-007-0008-5.
^ de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ (May 2002). "Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study". Circulation. 105 (18): 2159–65. PMID 11994249. doi:10.1161/01.CIR.0000015857.31889.7B.
^ Reuters (2007-10-04). "Merck announces its investigational CETP-Inhibitor, MK-0859, produced positive effects on lipids with no observed blood pressure changes". Reuters, Inc. Retrieved 26 November 2013.

External links

Cholesterol ester transfer proteins at the US National Library of Medicine Medical Subject Headings (MeSH)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. HDLコレステロール：異常値の臨床的側面 hdl cholesterol clinical aspects of abnormal values
2. 薬剤の効きづらい高コレステロール血症の治療 treatment of drug resistant hypercholesterolemia
3. リポ蛋白の分類、代謝、およびアテローム性動脈硬化症における役割 lipoprotein classification metabolism and role in atherosclerosis
4. リポ蛋白および止血因子に対する運動の影響 effects of exercise on lipoproteins and hemostatic factors
5. 高トリグリセリド血症患者に対するアプローチ approach to the patient with hypertriglyceridemia

English Journal

Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?

Mani P1, Rohatgi A.
Current atherosclerosis reports.Curr Atheroscler Rep.2015 Aug;17(8):521. doi: 10.1007/s11883-015-0521-x.
High-density lipoprotein cholesterol (HDL-C) has been shown in epidemiologic studies to be associated with cardiovascular (CV) risk and thus significant efforts have been focused on HDL-C modulation. Multiple pharmaceutical agents have been developed with the goal of increasing HDL-C. Niacin, the mo
PMID 26048725

Newly developed apolipoprotein A-I mimetic peptide promotes macrophage reverse cholesterol transport in vivo.

Shimizu T1, Tanigawa H1, Miura S2, Kuwano T1, Takata K1, Suematsu Y1, Imaizumi S1, Yahiro E1, Zhang B3, Uehara Y4, Saku K5.
International journal of cardiology.Int J Cardiol.2015 Aug 1;192:82-8. doi: 10.1016/j.ijcard.2015.05.012. Epub 2015 May 7.
BACKGROUND: We elucidated the effect of newly developed Fukuoka Apolipoprotein A-I Mimetic Peptide (FAMP) on in vivo macrophage reverse cholesterol transport (RCT) and the underlying mechanisms.METHODS AND RESULTS: Cholesteryl ester transfer protein transgenic mice were divided into FAMP, and placeb
PMID 26005953

Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials.

Ip CK1, Jin DM2, Gao JJ3, Meng Z4, Meng J5, Tan Z6, Wang JF7, Geng DF8.
International journal of cardiology.Int J Cardiol.2015 Jul 15;191:138-48. doi: 10.1016/j.ijcard.2015.04.228. Epub 2015 Apr 30.
BACKGROUND: In patients at high risk of atherosclerotic cardiovascular diseases (ASCVDs), residual cardiovascular risk persists despite the achievement of target LDL cholesterol levels with statin therapy. It is still unclear whether adding lipid-modifying agent to statin treatment can further impro
PMID 25965621

Japanese Journal

Two Adjacent Mutations on Chromosome 16 Discovered in a Patient Presenting with Generalized Convulsions after Influenza A Virus Infection

Iwasaki Yorihiro,Takahashi Makio,Nozu Kandai,Matsumoto Sadayuki,Koshiyama Hiroyuki
Internal Medicine 50(19), 2179-2183, 2011
… Initial laboratory tests revealed metabolic alkalosis with hypomagnesemia, as well as an elevated high density lipoprotein cholesterol level. … He was diagnosed with Gitelman's syndrome and cholesteryl ester transfer protein deficiency by identifying homozygous mutations of causative genes, SLC12A3 and CETP, respectively. …
NAID 130001087924

DPE-003 Effects of Pitavastatin on High Density Lipoprotein Cholesterol and Cholesterol Ester Transfer Protein in Patients with Metabolic Syndrome(DPE01,Metabolic Syndrome (H),Digital Poster Session (English),The 73rd Annual Scientific Meeting of The Japanese Circulation Society)

Kim Sang Hyun,Lee Hae Young,Kang Hyun Jae,Chung Woo Young,Kim Young Jin,Zo Joo Hee,Kim Myung A,Kim Hyo Soo,Kim Cheol Ho,Sohn Dae Won,Oh Byung Hee,Park Young Bae,Choi Yun Shik
Circulation journal : official journal of the Japanese Circulation Society 73(Supplement_I), 356, 2009-03-01
NAID 110007510637

HDLを標的とした心臓病治療戦略 : HDL-Cは上げるべきか?

朔啓二郎,横山信治,池脇克則 [他],三浦伸一郎,上原吉就
日本心臓病学会誌 =Journal of cardiology. Japanese edition 2(2), 131-140, 2008-09-15
NAID 10024422279

Related Pictures

★リンクテーブル★

リンク元	「コレステロールエステル転送蛋白」「CETP」
拡張検索	「cholesterol ester transfer protein deficiency」
関連記事	「transfer」「cholesterol ester」「cholesterol」

「コレステロールエステル転送蛋白」

CETP
Available structures
PDB	Human UniProt search: PDBe RCSB
List of PDB id codes
	4F2A, 2OBD, 4EWS
Identifiers
Aliases	CETP, BPIFF, HDLCQ10, cholesteryl ester transfer protein
External IDs	OMIM: 118470 HomoloGene: 47904 GeneCards: CETP
Gene location (Human)
Chr.	Chromosome 16 (human)
End	56,983,845 bp
RNA expression pattern
	More reference expression data
Gene ontology
Molecular function	• triglyceride binding; • phosphatidylcholine binding; • lipid transporter activity; • phospholipid transporter activity; • cholesterol binding; • cholesterol transporter activity; • lipid binding;
Cellular component	• vesicle; • extracellular region; • high-density lipoprotein particle; • extracellular exosome; • extracellular space;
Biological process	• steroid metabolic process; • phospholipid homeostasis; • lipid transport; • lipid metabolic process; • phospholipid transport; • cholesterol transport; • cholesterol metabolic process; • regulation of cholesterol efflux; • lipid homeostasis; • very-low-density lipoprotein particle remodeling; • triglyceride transport; • cholesterol homeostasis; • phosphatidylcholine metabolic process; • triglyceride metabolic process; • negative regulation of macrophage derived foam cell differentiation; • triglyceride homeostasis; • reverse cholesterol transport; • low-density lipoprotein particle remodeling; • high-density lipoprotein particle remodeling; • transport;
	Sources:Amigo / QuickGO
Orthologs
	1071
	n/a
	ENSG00000087237
	n/a
	P11597
	n/a
	NM_000078; NM_001286085
	n/a
	NP_000069; NP_001273014
	n/a
	Wikidata
View/Edit Human

　　[★]

英: cholesterol ester transfer protein, CETP
同: コレステロールエステル転送蛋白質
関: コレステロール逆転送、高比重リポ蛋白

[show details]

コレステリルエステル転送たんぱく : nothing
コレステロールエステル転送たんぱく : nothing
コレステリルエステル転送タンパク : 83 件
コレステロールエステル転送タンパク : 87 件
コレステリルエステル転送たんぱく質 : 約 30,500 件
コレステロールエステル転送たんぱく質 : 57 件
コレステリルエステル転送タンパク質 : nothing
コレステロールエステル転送タンパク質 : 57 件
コレステリルエステル転送蛋白 : 約 29,800 件
コレステロールエステル転送蛋白 : 約 33,000 件
コレステリルエステル転送蛋白質 : 45 件
コレステロールエステル転送蛋白質 : 52 件

en

cholesterol ester transfer protein : 約 668,000 件
cholesteryl ester transfer protein : 約 108,000 件

血中のHDLに含まれるコレステロールエステルを、IDLやLDLに転送する血中のタンパク質

コレステロールの逆転送

末梢組織のコレステロールはHDLにより運び出され、血中でレシチンコレステロールアシルトランスフェラーゼ(LCAT）によりエステル化される。コレステロールエステルはCETPによりIDL、LDLに受け渡され肝臓へ逆輸送される

臨床関連

高HDL血症

CETPの機能欠損により生じる

「CETP」

　　[★] コレステロールエステル転送蛋白 cholesterol ester transfer protein

「cholesterol ester transfer protein deficiency」

　　[★] コレステロールエステル転送蛋白欠損症

「transfer」

　　[★]

n.

伝達、移動、転移、移行、(医療)移植

v.

伝達する、移動する、移行させる、移植する、移す、トランスファーする

関: communication、convey、dissemination、engraft、engraftment、entry、graft、grafting、immigration、implant、implantation、metastases、metastasis、metastasize、migrate、move、movement、run、shift、transduce、transduction、transductional、transference、transit、transition、transitional、translocate、translocation、transmission、transmit、transplant、transplantation、travel

「cholesterol ester」

　　[★]

コレステロールエステル

関: cholesteryl ester

同: CE

「cholesterol」

　　[★] コレステロール　　

[WikiPathways-16] The interactive pathway map can be edited at WikiPathways: "Statin_Pathway_WP430".

[refGRCh38Ensembl-1] GRCh38: Ensembl release 89: ENSG00000087237 - Ensembl, May 2017

[2] "Human PubMed Reference:".

[Zhong1996-3] Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR (June 1996). "Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels". J Clin Invest. 97 (12): 2917–23. PMC 507389 . PMID 8675707. doi:10.1172/JCI118751.

[4] Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, Lipton R, Cheng S, Shuldiner AR (October 2003). "Unique lipoprotein phenotype and genotype associated with exceptional longevity". JAMA. 290 (15): 2030–40. PMID 14559957. doi:10.1001/jama.290.15.2030.

[pmid19242900-5] Darabi M, Abolfathi AA, Noori M, Kazemi A, Ostadrahimi A, Rahimipour A, Darabi M, Ghatrehsamani K (2009). "Cholesteryl ester transfer protein I405V polymorphism influences apolipoprotein A-I response to a change in dietary fatty acid composition". Horm Metab Res. 41 (7): 554–8. PMID 19242900. doi:10.1055/s-0029-1192034.

[6] Bruce C, Sharp DS, Tall AR (1 May 1998). "Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia". J Lipid Res. 39 (5): 1071–8. PMID 9610775.

[pmid8018112-7] Abbey M, Nestel PJ (March 1994). "Plasma cholesteryl ester transfer protein activity is increased when trans-elaidic acid is substituted for cis-oleic acid in the diet". Atherosclerosis. 106 (1): 99–107. PMID 8018112. doi:10.1016/0021-9150(94)90086-8.

[8] Barter PJ, Brewer HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR (February 2003). "Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis". Arterioscler Thromb Vasc Biol. 23 (2): 160–7. PMID 12588754. doi:10.1161/01.ATV.0000054658.91146.64.

[9] Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ (April 2004). "Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol". N Engl J Med. 350 (15): 1505–15. PMID 15071125. doi:10.1056/NEJMoa031766.

[10] Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Lasala GP, Tuzcu EM (March 2007). "Effect of torcetrapib on the progression of coronary atherosclerosis". N Engl J Med. 356 (13): 1304–16. ISSN 0028-4793. PMID 17387129. doi:10.1056/NEJMoa070635.

[11] Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML (April 2007). "Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia". N Engl J Med. 356 (16): 1620–30. PMID 17387131. doi:10.1056/NEJMoa071359.

[FDA2006-12] "Pfizer Stops All Torcetrapib Clinical Trials in Interest of Patient Safety" (Press release). U.S. Food and Drug Administration. 2006-12-03.

[13] El Harchaoui K, van der Steeg WA, Stroes ES, Kastelein JJ (August 2007). "The role of CETP inhibition in dyslipidemia". Curr Atheroscler Rep. 9 (2): 125–33. PMID 17877921. doi:10.1007/s11883-007-0008-5.

[14] Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ (May 2002). "Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study". Circulation. 105 (18): 2159–65. PMID 11994249. doi:10.1161/01.CIR.0000015857.31889.7B.

[15] Reuters (2007-10-04). "Merck announces its investigational CETP-Inhibitor, MK-0859, produced positive effects on lipids with no observed blood pressure changes". Reuters, Inc. Retrieved 26 November 2013.

v t e Proteins: carrier proteins
Fatty acid	FABP1 FABP2 FABP3 FABP4 FABP5 FABP6 FABP7
Hormone	peptide hormone: Follistatin Growth hormone binding protein Insulin-like growth factor binding protein IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6 IGFBP7 Neurophysins Neurophysin I II steroid hormone: Sex hormone binding globulin/Androgen binding protein Transcortin Thyroxine-binding globulin Transthyretin
Metal/element	calcium Calcium-binding protein Calmodulin-binding proteins copper Ceruloplasmin iron Iron-binding proteins Transferrin receptor
Vitamin	Retinol binding protein 1 2 3 4 Transcobalamin
Pigment	Plant Light-Harvesting Complex Orange Carotenoid Protein Phycobiliprotein Photosynthetic Reaction Centers Phytochrome Rhodopsin
Other	Acyl carrier protein Adaptor protein Cholesterylester transfer protein F-box protein GTP-binding protein Latent TGF-beta binding protein Major urinary proteins Membrane transport protein Odorant binding protein

v t e Lipids: lipoprotein particle metabolism
Lipoprotein particle classes and subclasses	delivery of TGs: Chylomicron VLDL delivery of C and CE: IDL LDL lb LDL sd LDL Lp(a) HDL Remnant cholesterol
Apolipoproteins	APOA 1 2 4 5 APOB APOC 1 2 3 4 APOD APOE APOH SAA SAA1
Extracellular enzymes	LCAT LIPC LPL
Lipid transfer proteins	CETP MTTP PLTP
Cell surface receptors	HDL: SCARB1 IDL: LRP LRP1 LRP1B LRP2 LRP3 LRP4 LRP5 LRP5L LRP6 LRP8 LRP10 LRP11 LRP12 LDL: LDLR LRPAP1
ATP-binding cassette transporter	ABCA1 ABCG5 ABCG8

匿名

検索

案内

案内

cholesterol ester transfer protein